Quintrio
Home

PHARMACEUTICAL PREPARATIONS

uniQure N.V.

QURE

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Last trade $20.87
Day change -$1.01 (-4.62%)
Day range $20.56 – $22.45
Volume 789,632
Market cap $1.53B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.53B
Price / earnings
—
Price / book
5.21×
Price / sales
76.1×
EV / sales
73.71×
EV / EBITDA
-8.49×

Profitability

Earnings per share
-$3.32
Return on assets
-24.76%
Return on equity
-79.04%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.17×
Current ratio
11.52×
Quick ratio
11.52×
Cash ratio
1.64×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$192.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for QURE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$5.2M$5.84M$3.56M$5.57M$3.7M$5.26M$1.57M$5.22M
Cost of revenue$236K$350K$219K$435K$398K$656K$197K$17.68M
Gross profit$4.96M$5.49M$3.34M$5.13M$3.3M$4.61M$1.37M-$12.46M
Selling, general and administrative$23.92M$17.37M$20.07M$21.61M$19.44M$13.5M$10.91M$11.38M
Research and development$35.52M$33.96M$29.18M$34.78M$34.37M$35.38M$36.14M$38.84M
Total operating expenses$59.63M$57.69M$49.06M$43.84M$55.85M$48.47M$40.7M$27.42M
Operating income-$54.67M-$52.2M-$45.72M-$38.71M-$52.55M-$43.87M-$39.33M-$39.88M
Interest expense-$14.58M-$14.37M-$14.03M-$14.57M-$16.72M-$15.59M-$15.11M-$14.88M
Income before taxes-$60.54M-$79.22M-$53.05M-$41M-$71.9M-$37.29M-$43.14M-$72.41M
Income taxes$676K$1.84M$488K-$3.92M$8.63M$425K$496K$856K
Net income-$61.22M-$81.06M-$53.54M-$37.09M-$80.53M-$37.72M-$43.64M-$73.26M
Net income attributable to common shareholders-$61.22M-$81.06M-$53.54M-$37.09M-$80.53M-$37.72M-$43.64M-$73.26M
EBITDA-$49.22M-$47.3M-$42.76M-$35.74M-$48.91M-$40.24M-$34.8M-$35.52M
Basic earnings per share-$0.88-$1.22-$0.85-$0.58-$1.38-$0.69-$0.82-$1.50
Diluted earnings per share-$0.88-$1.22-$0.85-$0.58-$1.38-$0.69-$0.82-$1.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure's lead gene therapy candidate, ifezuntirgene inilparvovec, for Huntington's disease has received FDA Priority Review with a May 1, 2027 decision date. The company plans to launch a confirmatory study by end of 2026 targeting 200 patients. While the regulatory milestone drove a 17.5% stock surge, mixed clinical data, widening loss estimates, and pipeline risks temper the outlook. The company maintains a strong cash position of $768.4 million expected to fund operations through 2030.

Zacks Investment Research

3 Promising Genomics Stocks to Add to Your Portfolio Now

The global genomics market is projected to reach $99.26 billion by 2034, growing at 12.66% CAGR. Three stocks—Illumina, uniQure, and 10x Genomics—are highlighted as potential investments in this expanding sector, all carrying Zacks Rank #2 (Buy) ratings. Recent advances in DNA sequencing, gene therapies, and genome-editing technologies like CRISPR are driving growth in personalized medicine and synthetic biology applications.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.

GlobeNewswire Inc.

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.

Zacks Investment Research

uniQure Plunges on Additional Data From Huntington's Disease Study

uniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls. However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.